PI3K Inhibitor D-116883 is Effective in In Vitro Models of Ovarian Cancer

• Published in: Anticancer research Vol. 32; no. 5; pp. 2035 - 2041
• Main Authors: HONIG, A, HAHNE, J. C, MEYER, S, KRANKE, P, HAUSLER, S, DIESSNER, J, DIETL, J, ENGEL, J. B
• Format: Conference Proceeding Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01-05-2012
• Subjects: Amino Acid Chloromethyl Ketones - pharmacology; Antineoplastic Agents - pharmacology; Biological and medical sciences; Cell Cycle - drug effects; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Imidazoles - pharmacology; Indoles - pharmacology; Medical sciences; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Phosphatidylinositol 3-Kinases - antagonists & inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt - antagonists & inhibitors; Proto-Oncogene Proteins c-akt - metabolism; Tumors; Enzyme; oral tumor treatment; small molecules/biologicals; Transferases; Ovary cancer; Akt protein kinase; Malignant tumor; In vitro; Female genital diseases; 1-Phosphatidylinositol 3-kinase; Ovarian cancer; PI3K/AKT pathway; Resistance; Ovarian diseases; Cancerology; Treatment; PI3K; Efficiency; platin resistance; Inhibitor; Models; Cancer
• EISSN: 1791-7530
• ISSN: 0250-7005

D-116883 (Aeterna Zentaris GmbH, Frankfurt, Germany) is an orally effective drug that acts via inhibition of phosphatidylinositol 3-kinase (PI3K). The PI3K/AKT signal transduction pathway is involved in ovarian cancer tumorigenesis. Phosphatase and Tensin homolog (PTEN) loss and other activating mutations frequently contribute to the activation of this pathway. We tested whether D-116883 exerts cytostatic effects in in vitro models of ovarian cancer and analyzed the induced programmed cell death.
We evaluated the potency of D-116883 in four ovarian carcinoma cell lines with different cellular assays. The effects of D-116883 on cell proliferation was analysed by crystal-violet staining and tetrazolium salt [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MTT] assay. The capacity for anchorage-independent growth was analyzed in two ovarian carcinoma cell lines without and with D-116883 addition by using the soft agar assay. Fluorescence activated cell sorting (FACS) cell cycle analyses were performed. Cells were incubated with multicaspase inhibitor benzyloxycarbonyl-val-ala-asp(OMe)-fluoromethylketone (zVAD) and inhibitor of necroptosis necrostatin.
Growth inhibition occurred in all ovarian carcinoma cell lines studied (A2780, A2780cis, OAW42 and SKOV3) in a micromolar range (IC(50)<1 μM). By using soft agar assay, a reduced capacity for anchorage-independent growth, a hallmark of tumor cells, caused by D-116883 was demonstrated. Cell cycle analyses showed that D-116883 dose-dependently increased apoptotic cells. Multicaspase inhibitor zVAD and inhibitor of necroptosis necrostatin did not abrogate the growth-inhibiting effect of the compound.
PI3K inhibitor D-116883 showed substantial cytotoxic effects in various in vitro models of ovarian cancer. Our results make D-116883 a good candidate for further ovarian cancer research including in vivo experiments.